TMS progress monitoring: what to measure, when, and what the numbers mean
A standard acute TMS course runs about 36 sessions over six to nine weeks, and payers increasingly expect documented symptom measurement across it rather than a clinical impression at the end. Progress monitoring in TMS has three jobs: prove response and remission while the course is running, produce the documentation that supports continued authorization, and catch relapse after taper early enough that retreatment is a decision rather than a crisis.
A measurement schedule that matches the treatment course
Weekly measurement during the acute course is the practical standard. It is frequent enough to distinguish real improvement from ordinary week-to-week variation, and it produces a score at every point a payer is likely to ask about — baseline, mid-course, end of acute course and post-taper.
| Point in treatment | Timing | Instruments | What the score is used for |
|---|---|---|---|
| Baseline | Before session 1 | PHQ-9, GAD-7, ISI if sleep is affected | Authorization baseline and the anchor for every later comparison |
| Early course | Sessions 5-10 | PHQ-9 | Confirm engagement and tolerability; too early to judge response |
| Mid-course review | Sessions 15-20 | PHQ-9, GAD-7 | The point most plans expect documented improvement for continued authorization |
| Late acute course | Sessions 25-30 | PHQ-9 | Decide on extension, taper plan or protocol change |
| End of acute course | Sessions 30-36 | PHQ-9, GAD-7, function measure | Document response or remission and set the maintenance baseline |
| Taper | Weekly through taper | PHQ-9 | Detect worsening while sessions are still being delivered |
| Post-course follow-up | Monthly for 12 months | PHQ-9 | Early relapse detection and the retreatment decision |
Response, remission and non-response — the definitions to write down
These thresholds are what make a chart note defensible. Vague language about a patient 'doing better' does not support authorization or a retreatment request; a percentage change from a documented baseline does.
| Outcome | Definition | Example (baseline PHQ-9 of 20) | Implication |
|---|---|---|---|
| Remission | Total below 5 | Score of 4 or lower | Plan taper and maintenance monitoring |
| Response | 50% or greater reduction from baseline | Score of 10 or lower | Continue the course; document the improvement |
| Partial response | 25-49% reduction | Score of 11-15 | Consider extending the course or adjusting the protocol |
| Non-response | Under 25% reduction by session 20-25 | Score above 15 | Reassess diagnosis, adherence, protocol and comorbidity |
| Reliable worsening | 5-point increase from the best score achieved | Best of 6, now 11 or higher | Investigate before it becomes a full relapse |
Why relapse after TMS is the measurement problem that matters
Most patients who respond to an acute course are discharged into far less frequent contact. Relapse, when it happens, usually develops over weeks — sleep goes first, then energy and interest, then mood — and the patient often does not call until the decline is well established. By then a short retreatment or a maintenance session may no longer be sufficient.
Monthly measurement in the year after a course turns that into a visible trend line. A 5-point rise from the post-treatment best is a signal worth a phone call; two consecutive rises is a signal worth a visit. The point is not to alarm anyone, it is to make the retreatment conversation happen while the patient is still functioning.
- Track from the best score achieved during the course, not from baseline — relapse is movement away from the gain.
- Watch the sleep and anhedonia items specifically; they commonly move before the total does.
- PHQ-9 Item 9 at 1 or higher after a course is a same-day safety conversation, regardless of the total.
- Record whether the patient is on maintenance sessions, medication or neither, so a rise can be interpreted in context.
Documentation payers ask for
- A baseline score from a validated instrument, dated before the first treatment session.
- Failed adequate trials of antidepressant medication, with drug, dose and duration — the usual medical-necessity criterion for initial authorization.
- Interval scores across the course, most importantly a mid-course score showing direction of change.
- An end-of-course score with an explicit response or remission statement expressed as percentage change from baseline.
- For retreatment: the documented gain from the previous course, the post-course scores showing loss of that gain, and the date the decline began.
- Coverage criteria vary by plan and state. Confirm the specific requirements with each payer rather than assuming a common standard.
Which instruments to use alongside the PHQ-9
The PHQ-9 carries most of the weight because it is free, brief, sensitive to change and the instrument quality measures are built around. Adding one or two targeted measures makes the record more useful without turning every visit into a questionnaire session.
| Instrument | Items | Why add it | Cadence |
|---|---|---|---|
| GAD-7 | 7 | Comorbid anxiety is common and often the reason a patient still feels unwell at a low PHQ-9 | Baseline, mid-course, end of course |
| ISI | 7 | Sleep frequently improves first and deteriorates first; a useful early signal | Baseline then monthly |
| PCL-5 | 20 | Trauma history changes the interpretation of a plateau | Baseline, and again if progress stalls |
| AUDIT-C | 3 | Alcohol use undermines response and is easy to miss | Baseline and every few months |
| Function measure | Varies | Payers and patients both care about work and role function, not only symptom counts | Baseline and end of course |
Making it happen without adding clinic work
The reason TMS clinics stop measuring is administrative, not clinical: someone has to remember to hand out a form, score it, and put the number somewhere findable. Automating the send, the reminder, the scoring and the trend removes the part that fails.
- Assessments go out by email on a schedule tied to the treatment course, so nobody has to remember.
- Scoring and severity banding happen on submission, with the trend plotted against days from treatment start.
- Threshold alerts fire on suicidality items and on reliable worsening, routed to the treating clinician.
- Post-course monitoring continues automatically for 12 months, which is where relapse actually shows up.
- Score histories export as a branded PDF or CSV for authorization requests and payer conversations.
The workflow end to end
1. Baseline before session 1
PHQ-9 plus GAD-7, and ISI if sleep is part of the picture. This is the number every later comparison depends on.
2. Weekly measurement through the acute course
One brief instrument, sent automatically, scored on submission.
3. Mid-course review at sessions 15-20
Compare to baseline as a percentage. Document direction of change for continued authorization.
4. End-of-course determination
State remission, response, partial response or non-response explicitly, with the numbers behind it.
5. Taper with continued measurement
Keep measuring weekly while sessions taper — this is when early worsening is most treatable.
6. Twelve months of monthly follow-up
Track against the best score achieved. A 5-point rise triggers outreach.
7. Retreatment decision with evidence
Present the documented gain, the documented loss, and the dates. That is the case a payer can act on.
Related tools and guides
PHQ-9 form and scoring
The instrument most TMS monitoring is built on
Early relapse detection
How worsening is detected and escalated
GAD-7 scoring guide
Comorbid anxiety alongside a depression course
Insomnia Severity Index scoring
Sleep as an early signal
Depression screening hub
Screening, severity and follow-up
Pricing
What automated monitoring costs per clinician
Frequently asked questions
How often should symptoms be measured during a TMS course?
Weekly during the acute course is the practical standard, with a formal review at sessions 15-20 and again at the end of the course. Weekly measurement is frequent enough to separate genuine improvement from normal variation and gives you a score at every point a payer may ask about.
Which instrument is used for TMS progress monitoring?
The PHQ-9 in most clinics: it is free, takes two minutes, is sensitive to change, and remission and response are defined against it. GAD-7 and the ISI are common additions where anxiety or sleep are part of the presentation.
What counts as response and remission in TMS?
Response is a 50% or greater reduction from the baseline score; remission is a PHQ-9 total below 5. Both should be documented as a percentage change from a dated baseline rather than as a clinical impression.
What if a patient has not improved by session 20?
Less than a 25% reduction by sessions 20-25 counts as non-response and should prompt review of diagnosis, adherence, protocol parameters, medication and comorbid anxiety, trauma or substance use — not simply more sessions.
How long should monitoring continue after the course ends?
Twelve months of monthly measurement is a reasonable standard, because relapse typically emerges weeks to months after taper. Track against the best score achieved during the course; a 5-point rise from that best is worth outreach.
What documentation supports TMS retreatment authorization?
The documented gain from the previous course, post-course scores showing that gain being lost, the date the decline started, and a current score. A continuous score history makes that case in one page.
Can outcome tracking be automated so staff do not have to chase forms?
Yes. Assessments can be emailed on a schedule tied to the treatment course, scored automatically on submission, plotted against days from treatment start, and escalated by alert when a threshold or a crisis item is triggered.
References
- PHQ-9 validation: Kroenke, Spitzer & Williams (2001), J Gen Intern Med 16(9):606-613. A 5-point change is the commonly cited minimum clinically important difference.
- Remission on the PHQ-9 is conventionally defined as a total below 5; response as a 50% or greater reduction from baseline.
- Clinical TMS Society consensus review (Perera et al., 2016, Brain Stimulation) describes standard acute course structure and the role of outcome measurement.
- Coverage criteria for initial TMS authorization and retreatment are payer-specific; confirm current policy with each plan.
Educational information for clinicians. Screening results are not a diagnosis and do not replace clinical assessment. If you or someone you know is in crisis, call or text 988 for the Suicide & Crisis Lifeline.
